These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32442891)

  • 1. Attitudes and knowledge about cannabis and cannabis-based therapies among US neurologists, nurses, and pharmacists.
    Szaflarski M; McGoldrick P; Currens L; Blodgett D; Land H; Szaflarski JP; Segal E
    Epilepsy Behav; 2020 Aug; 109():107102. PubMed ID: 32442891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis Treatment in Children with Epilepsy: Practices of Canadian Neurologists.
    DeGasperis SM; Webster R; Pohl D
    Can J Neurol Sci; 2020 Jul; 47(4):511-518. PubMed ID: 32127067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis.
    Bawa Z; Saini B; McCartney D; Bedoya-Pérez M; McLachlan AJ; McGregor IS
    Int J Clin Pharm; 2023 Apr; 45(2):375-386. PubMed ID: 36446995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of Pharmacists' Knowledge of Connecticut's Medical Cannabis Program.
    Reece SM; Holle L; Mukherjee K
    Cannabis Cannabinoid Res; 2021; 6(1):66-73. PubMed ID: 33614954
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurologists' perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: A qualitative interview study.
    Elliott J; DeJean D; Potter BK; Coyle D; Clifford T; McCoy B; Wells GA
    Seizure; 2020 May; 78():118-126. PubMed ID: 32361185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis use for symptom relief in multiple sclerosis: A cross-sectional survey of webinar attendees in the US and Canada.
    Hildebrand A; Minnier J; Cameron MH
    Mult Scler Relat Disord; 2020 Feb; 38():101516. PubMed ID: 31855842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Survey of neurologists regarding their attitudes toward medicinal cannabis and the effects of evidence-based cannabis education].
    Masataka Y; Ikeda T; Ando Y
    Rinsho Shinkeigaku; 2019 Jul; 59(7):405-411. PubMed ID: 31243253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in Cannabidiol-Related Attitudes and Practice Behaviors Between U.S. Primary Care Physicians Practicing in a Single Health Care System Across States With and Without Marijuana Legalization.
    Sharma P; Wilfahrt RP; Lackore K; Hammond CJ
    Cannabis Cannabinoid Res; 2024 Aug; 9(4):1038-1047. PubMed ID: 37220016
    [No Abstract]   [Full Text] [Related]  

  • 9. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
    Mead A
    Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cannabis and its products among patients in a tertiary epilepsy center: A cross-sectional survey.
    Puteikis K; Mameniškienė R
    Epilepsy Behav; 2020 Oct; 111():107214. PubMed ID: 32580133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knowledge of and attitudes toward epilepsy surgery among neurologists in Saudi Arabia.
    Aljafen B; Alomar M; Abohamra N; Alanazy M; Al-Hussain F; Alhumayyd Z; Mohammad Y; Muayqil T
    Neurosciences (Riyadh); 2020 Jan; 25(1):43-49. PubMed ID: 31982894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia's survey.
    Mathern GW; Beninsig L; Nehlig A
    Epilepsia; 2015 Jan; 56(1):1-6. PubMed ID: 25413126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marijuana use among patients with epilepsy at a tertiary care center.
    Kerr A; Walston V; Wong VSS; Kellogg M; Ernst L
    Epilepsy Behav; 2019 Aug; 97():144-148. PubMed ID: 31252269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of Wisconsin pharmacists about cannabinoid products: Are we ready to recommend?
    Emmerling S; Martin B; Schmitz N
    J Am Pharm Assoc (2003); 2021; 61(6):e71-e75. PubMed ID: 34456146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Arkansans' attitudes toward pharmacist involvement and regulation of medical cannabis following its availability in Arkansas.
    Hernandez M; Franks AM; Payakachat N
    J Am Pharm Assoc (2003); 2023; 63(4):1131-1137.e4. PubMed ID: 37207711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey.
    Karanges EA; Suraev A; Elias N; Manocha R; McGregor IS
    BMJ Open; 2018 Jul; 8(7):e022101. PubMed ID: 29970456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the preparedness and future-readiness of Malaysian community pharmacists in Klang Valley regarding the use of medical marijuana.
    Kuang FW; Farrukh MJ
    BMC Health Serv Res; 2024 Apr; 24(1):524. PubMed ID: 38664704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers.
    Philpot LM; Ebbert JO; Hurt RT
    BMC Fam Pract; 2019 Jan; 20(1):17. PubMed ID: 30669979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of education in a community hospital on healthcare providers' knowledge of and attitudes toward medical marijuana.
    Meyers S; Gant K; Burmeister M
    Curr Pharm Teach Learn; 2024 Jun; 16(6):396-403. PubMed ID: 38538449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Cannabis.
    Ebbert JO; Scharf EL; Hurt RT
    Mayo Clin Proc; 2018 Dec; 93(12):1842-1847. PubMed ID: 30522595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.